Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance (MGRS)-related lesions in Latin America.
Monoclonal gammopathy of renal significance (MGRS)-related lesions are infrequent entities. There are no publications on these disorders in Latin America (LA). The aim of this study was to describe epidemiological and clinical characteristics of these patients in LA. We performed a multicenter retrospective study. Patients with diagnosis of MGRS between 2012 and 2018 were included. Epidemiological and clinical data were collected from clinical records. Twenty seven patients from Chile, Argentina, Ecuador and Uruguay were included. Half debuted with a nephrotic syndrome, and 32% required dialysis. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) was found in 33%, amyloidosis in 26%, and monoclonal immunoglobulin deposition disease (MIDD) also in 26%. The immunoglobulin most frequently found in renal biopsies was IgG Kappa. In 67% a paraprotein was found. Twenty patients received an anti-plasma cell regimen, and 3 a rituximab-based regimen (IgM-MGRS). Renal response was achieved in 56%. Early treatment (≤ 3 months) was associated with higher renal responses (75% vs 43%). Three patients relapsed within 21.5 months, and 3 progressed: 1 to multiple myeloma, 1 to systemic amyloidosis and another to systemic LCDD. Two patients died, both due infection during induction treatment. There was a higher than expected frequency of patients requiring dialysis. The most common MGRS-related lesion was PGNMD. Early treatment was associated with better response. As a rare disease, increasing awareness and promoting early diagnosis are necessary in LA to improve outcomes. This article is protected by copyright. All rights reserved.